These findings warrant confirmation in the ongoing phase 2 FIGHT-209 study (NCT05267106) of pemigatinib in patients with recurrent GBM and other CNS tumors with activating FGFR1-3 mutations or fusions/rearrangements.6 The gene discussed is FGFR1; the disease is glioblastoma.